e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial
Stephen Milne, Xuan Li, Chen Xi Yang, Fernando Sergio Leitao Filho, Ana I. Hernández Cordero, Cheng Wei Tony Yang, Tawimas Shaipanich, Stephan F. van Eeden, Janice M. Leung, Stephen Lam, Don D. Sin
Source:
Eur Respir J, 58 (1) 2100130; 10.1183/13993003.00130-2021
Journal Issue:
July
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Stephen Milne, Xuan Li, Chen Xi Yang, Fernando Sergio Leitao Filho, Ana I. Hernández Cordero, Cheng Wei Tony Yang, Tawimas Shaipanich, Stephan F. van Eeden, Janice M. Leung, Stephen Lam, Don D. Sin. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial. Eur Respir J, 58 (1) 2100130; 10.1183/13993003.00130-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial
Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID
Year: 2021
Omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists: Results of a phase IIIb randomized controlled trial
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Inhaled corticosteroids in patients with mild to moderate COPD with and without airway hyperresponsiveness to mannitol: A randomized placebo controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
How to reduce COPD exacerbations with inhaled drugs? A pooled analysis of randomized trials
Source: Annual Congress 2008 - Organisation of care and management of COPD
Year: 2008
The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial
Source: Eur Respir J, 57 (6) 2003338; 10.1183/13993003.03338-2020
Year: 2021
Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006
Inhaled steroids doses to obtain asthma control in children: a randomised concurrent cohort study
Source: Annual Congress 2009 - Clinical advances in childhood asthma
Year: 2009
A randomized placebo and active controlled trial of AZD8871 a novel dual acting bronchodilator in COPD patients
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017
Cardioselective beta-blockers are not only safe in patients with COPD, but may also improve the responsibility of FEV1 to beta-agonist: A meta-analysis of randomized controlled double-blinded trials
Source: Annual Congress 2012 - Pharmacological and non-pharmacological management of COPD
Year: 2012
Clinical effectiveness of MDI-HFA-Modulite beclomethasone in the treatment of asthma – meta-analysis of randomized controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006
Reframing asthma and inhaled corticosteroids (ICS) to modify treatment beliefs: an online randomised controlled trial
Source: International Congress 2018 – Educational tools to improve your practice
Year: 2018
Lower incidence of asthma exacerbations with F
E
NO-guided anti-inflammatory treatment: A randomised controlled trial
Source: Annual Congress 2012 - Effectiveness of respiratory disease management in primary care
Year: 2012
Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma
Source: Eur Respir J 2016; 47: 981-984
Year: 2016
Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
Source: ERJ Open Res 2016: 00055-2016
Year: 2016
ß-blockers in exacerbations of COPD: feasibility of a randomised controlled trial
Source: ERJ Open Res, 3 (1) 00090-2016; 10.1183/23120541.00090-2016
Year: 2017
Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
Self-titration of inhaled corticosteroid and ß
2
-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial
Source: Eur Respir J, 56 (4) 2000170; 10.1183/13993003.00170-2020
Year: 2020
Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study
Source: Eur Respir J, 58 (1) 2001798; 10.1183/13993003.01798-2020
Year: 2021
A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept